Skip to main content

Pyxis Oncology, Inc.

PYXS
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001782223

In the last 90 days, Pyxis Oncology, Inc. insiders filed 1 open-market purchase and 0 sales; 76 institutions reported holding it in 13F filings for Q2 2026, worth $101.1M in total; no superinvestor holds it.

Q3 2025 vs. Q2 2025

How the institutions holding Pyxis Oncology, Inc. changed between Q2 2025 and Q3 2025.

All holders in Q3 2025All holders in Q2 2025

13F holders of PYXS: Q2 2025 compared with Q3 2025
MeasureQ2 2025Q3 2025Change
Holders7473−1
Shares27.5M26.8M−628.2K (−2.3%)
Value$30.2M$59.7M+$29.5M (+97.8%)

New holders (14)

Institutions that held Pyxis Oncology, Inc. at the end of Q3 2025 but not at the end of Q2 2025.

Institutions new to PYXS in Q3 2025
InstitutionSharesValue% of portfolio
Perceptive Advisors LLC1,178,307$2.62M0.08%
StemPoint Capital LP689,538$1.53M0.31%
Longaeva Partners L.P.503,214$1.12M0.24%
Driehaus Capital Management LLC418,632$929.4K0.01%
Citadel Advisors LLC337,359$748.9K0.00%
Diadema Partners LP150,000$333.0K0.23%
Walleye Capital LLC119,561$265.4K0.00%
Jacobs Levy Equity Management, Inc60,333$133.9K0.00%
Two Sigma Advisers, LP52,524$116.6K0.00%
Two Sigma Investments, LP46,501$103.2K0.00%
Persistent Asset Partners Ltd34,632$76.9K0.06%
Cubist Systematic Strategies, LLC33,061$73.4K0.00%
Prudential Financial Inc16,300$36.2K0.00%
SRS Capital Advisors, Inc.14$310.00%

Sold out (15)

Institutions that held Pyxis Oncology, Inc. at the end of Q2 2025 and filed for Q3 2025 without it.